Short answer
HAEMONETICS CORP (HAE) filed an 8-K current report with the SEC on July 28, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Martin Madaus elected Haemonetics director effective July 24, 2026.
HAEMONETICS CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Martin Madaus elected Haemonetics director effective July 24, 2026
- Expected Audit and Governance and Compliance Committee assignments
- Shareholder election scheduled for 2027 annual meeting
- Annual equity compensation approximately $200,000 plus standard director compensation
- Healthcare investment experience at Carlyle Group since 2019 adds industry and portfolio oversight expertise
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 92.53% quorum; all eight director nominees elected for one-year terms ending 2027
- Executive compensation received advisory approval, 39,212,253 for versus 572,620 against
- Ernst & Young LLP ratified as independent auditor for fiscal year ending April 3, 2027
- 2019 Long-Term Incentive Compensation Plan amendment approved, 37,730,923 votes for
- 2007 Employee Stock Purchase Plan amendment approved, 39,766,894 votes for
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other HAEMONETICS CORP 8-K filings
Get the next HAE 8-K as it lands
Follow HAE for push alerts, or ask the research agent what this filing means.